Table 2.

CRS-207 clinical and immune response summary

IDCancerDose levelLLO responseMesothelin responseRECISTSurvival, moPrior immunotherapy
≥15 mo OS
 001-001PDA108YesNoPD15GVAX
 001-002PDA108YesNESD30+GVAX
 003-001Mesothelioma108YesYesSD29+IFN-β gene transfera
 005-002NSCLC3 × 108NENENE23No
 004-002PDA109YesNoSD17GVAX
 005-001NSCLC109YesYesSD26+No
<15 mo OS
 002-001Ovarian108NENEPDNEbNo
 002-002Mesothelioma108NENEPD4No
 004-001Mesothelioma108NoNoPD5No
 001-004PDA3 × 108NEYesPD3No
 001-005PDA3 × 108NEYesNE3No
 005-003PDA3 × 108NENoNE7No
 001-003PDA109NEYesPD7No
 002-003NSCLC109YesNEPD5No
 002-004Mesothelioma109NENEPD1No
 003-002Ovarian109NoYesPD4IFN-β gene transfera
 003-003Mesothelioma1010NENENE5No

Abbreviations: GVAX (GM-CSF–based whole-cell vaccine); NE, not evaluable; +, subjects alive as of October 14, 2010. Survival reported as of October 14, 2010.

bCensored because of subject withdrawal of consent.

  • aAdenovirus-mediated IFN-β gene transfer.